The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Iopromida     N,N'-bis(2,3- dihydroxypropyl)-2,4,6...

Synonyms: Ultravist, iopromide, Iopromidum, Ultravist 150, Ultravist 240, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ultravist

  • A control group received iopromide 370 alone while the treatment group was injected with a iopromide-protaxel formulation at a dose of 74 micromol/l, which is far below protaxel levels inducing systemic toxicity [1].
  • Each examination included the entire kidneys and was performed after injection of 120 mL iopromide and 300 mg of iodine per milliliter given per 75 kg of body weight [2].
  • RESULTS: Single and double doses of iopromide did not affect infarction volume or neurologic performance [3].
  • We studied the effect of an ionic high osmolar contrast medium (Ioxitalamate), an ionic low osmolar contrast medium (Ioxaglate) and various nonionic low osmolar contrast media (Iopamidol, Iopromide and Iohexol) on thrombus growth in a rabbit jugular vein thrombosis model [4].
  • CONCLUSION: Bolus injection of the nonionic iopromide does not statistically significantly affect infarction volume or cerebral ischemia symptoms [3].

Psychiatry related information on Ultravist

  • Group 2 (n = 21) ingested 10-mL aliquots of nonionic iodinated contrast material (iopromide) with a concentration of 300 mg per milliliter with meals and snacks for 2 days before imaging, without diet modification or a cathartic [5].

High impact information on Ultravist

  • A further comparison between GFR determined with iohexol and iopromide, a new low-osmolarity, low-viscosity contrast medium, was also performed in a subgroup of patients.(ABSTRACT TRUNCATED AT 250 WORDS)[6]
  • New compounds, such as iodinated polymers for x-ray perfusion imaging and iopromide- or metrizamide-containing liposomes allowing liver enhancement are discussed [7].
  • However there was a more dramatic decrease in phosphorylation of the phosphorylated form of mammalian target of rapamycin (mTOR) and of the extracellular-signal regulated kinases (ERK) 1/2 caused by sodium diatrizoate than by iopromide [8].
  • All the patients underwent cystography in the supine position by retrograde filling of the bladder with a 50% dilute solution of 300 mgI/ml iopromide in serial increments of 50 ml up to a maximum of 350 ml [9].
  • CONCLUSION: These findings indicate that the determination of plasma clearance of iohexol/iopromide is a simple, rapid, and accurate method that can indeed be used for estimating GFR in ICU patients with normal renal function or even different degrees of renal insufficiency [10].

Chemical compound and disease context of Ultravist


Biological context of Ultravist


Anatomical context of Ultravist


Associations of Ultravist with other chemical compounds


Gene context of Ultravist


Analytical, diagnostic and therapeutic context of Ultravist

  • MATERIALS AND METHODS: One hundred two patients (64 men, 38 women) with neoplastic (n = 85) and nonneoplastic focal lesions (n = 17) were prospectively assigned to biphasic injection group A or B and received 180 mL of iopromide containing 370 or 300 mg of iodine per milliliter, respectively, during spiral CT [34].
  • Safety and efficacy of iopromide in cerebral arteriography [35].
  • Efficacy and safety of iopromide for excretory urography [36].
  • Acute cardiac tolerance of current contrast media and the new taxane protaxel using iopromide as carrier during porcine coronary angiography and stenting [37].
  • METHODS: Eleven patients with an indication for lumbar myelography received 10 mL iopromide 240 in an open, prospective, single-center study [18].


  1. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Scheller, B., Speck, U., Romeike, B., Schmitt, A., Sovak, M., Böhm, M., Stoll, H.P. Eur. Heart J. (2003) [Pubmed]
  2. Glomerular filtration rate measured by using triphasic helical CT with a two-point Patlak plot technique. Hackstein, N., Wiegand, C., Rau, W.S., Langheinrich, A.C. Radiology. (2004) [Pubmed]
  3. Are iodinated contrast agents detrimental in acute cerebral ischemia? An experimental study in rats. Doerfler, A., Engelhorn, T., von Kummer, R., Weber, J., Knauth, M., Heiland, S., Sartor, K., Forsting, M. Radiology. (1998) [Pubmed]
  4. Variable effects of radiological contrast media on thrombus growth in a rabbit jugular vein thrombosis model. Levi, M., Biemond, B.J., Sturk, A., Hoek, J., ten Cate, J.W. Thromb. Haemost. (1991) [Pubmed]
  5. Tagging-based, electronically cleansed CT colonography: evaluation of patient comfort and image readability. Zalis, M.E., Perumpillichira, J.J., Magee, C., Kohlberg, G., Hahn, P.F. Radiology. (2006) [Pubmed]
  6. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. Gaspari, F., Perico, N., Ruggenenti, P., Mosconi, L., Amuchastegui, C.S., Guerini, E., Daina, E., Remuzzi, G. J. Am. Soc. Nephrol. (1995) [Pubmed]
  7. An overview of the clinical pharmacokinetics of x-ray contrast media. Bourin, M., Jolliet, P., Ballereau, F. Clinical pharmacokinetics. (1997) [Pubmed]
  8. Radiocontrast media cause dephosphorylation of Akt and downstream signaling targets in human renal proximal tubular cells. Andreucci, M., Fuiano, G., Presta, P., Esposito, P., Faga, T., Bisesti, V., Procino, A., Altieri, V., Tozzo, C., Memoli, B., Michael, A. Biochem. Pharmacol. (2006) [Pubmed]
  9. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. Yossepowitch, O., Lifshitz, D.A., Dekel, Y., Ehrlich, Y., Gur, U., Margel, D., Livne, P.M., Baniel, J. J. Urol. (2005) [Pubmed]
  10. Plasma clearance of iodine contrast media as a measure of glomerular filtration rate in critically ill patients. Erley, C.M., Bader, B.D., Berger, E.D., Vochazer, A., Jorzik, J.J., Dietz, K., Risler, T. Crit. Care Med. (2001) [Pubmed]
  11. Use of additives to contrast media to improve imaging in plain film and computed tomography urography. Krause, W., Schromm, M. Investigative radiology. (2003) [Pubmed]
  12. No pulmonary edema or congestion after central venous injection of conventional and newer contrast media in dogs. Böck, J., Heilbron, D.C., Hoeft, A., Korb, H., Hellige, G. Investigative radiology. (1988) [Pubmed]
  13. Pulmonary hypertension. Response of vasoactive peptides to a nonionic contrast medium in patients undergoing pulmonary angiography. Szolar, D.H., Saeed, M., Flueckiger, F., Preidler, K., Stiskal, M.A., Watzinger, N., Riepl, T., Horina, J. Investigative radiology. (1995) [Pubmed]
  14. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Carraro, M., Malalan, F., Antonione, R., Stacul, F., Cova, M., Petz, S., Assante, M., Grynne, B., Haider, T., Palma, L.D., Faccini, L. European radiology. (1998) [Pubmed]
  15. Low risk of contrast nephropathy in high-risk patients undergoing spiral computed tomography angiography with the contrast medium iopromide and prophylactic oral hydratation. Garcia-Ruiz, C., Martinez-Vea, A., Sempere, T., Sauri, A., Olona, M., Peralta, C., Oliver, A. Clin. Nephrol. (2004) [Pubmed]
  16. Pharmacokinetics of iopromide liposomes in rabbits. Schuhmann-Giampieri, G., Leike, J., Sachse, A., Krause, W. Pharm. Res. (1995) [Pubmed]
  17. Contrast media augmented apoptosis of cultured renal mesangial, tubular, epithelial, endothelial, and hepatic cells. Peer, A., Averbukh, Z., Berman, S., Modai, D., Averbukh, M., Weissgarten, J. Investigative radiology. (2003) [Pubmed]
  18. Pharmacokinetics and tolerability of iopromide 240 after lumbar myelography. Kugoev, A.I., Krause, W., Timerbaeva, S.L., Wegener, R. Investigative radiology. (1999) [Pubmed]
  19. Comparative cytotoxicity of low-osmolar nonionic and high-osmolar ionic contrast media to dog gallbladder epithelial cells. Ju, Y.M., Kim, M.H., Lee, S.K., Seo, D.W., Min, Y.I., Kim, J.Y. Gastrointest. Endosc. (2002) [Pubmed]
  20. Characterization of continuously extruded iopromide-carrying liposomes for computed tomography blood-pool imaging. Leike, J.U., Sachse, A., Rupp, K. Investigative radiology. (2001) [Pubmed]
  21. Pharmacochemical profile of iopromide. Muetzel, W., Speck, U. AJNR. American journal of neuroradiology. (1983) [Pubmed]
  22. Effects of angiographic contrast media on venous endothelium of rabbits. Thiesen, B., Mützel, W. Investigative radiology. (1990) [Pubmed]
  23. High iodine concentration contrast material for noninvasive multislice computed tomography coronary angiography: iopromide 370 versus iomeprol 400. Cademartiri, F., de Monye, C., Pugliese, F., Mollet, N.R., Runza, G., van der Lugt, A., Midiri, M., de Feyter, P.J., Lagalla, R., Krestin, G.P. Investigative radiology. (2006) [Pubmed]
  24. Iodinated radiographic contrast media inhibit shear stress- and agonist-evoked release of NO by the endothelium. Hutcheson, I.R., Griffith, T.M., Pitman, M.R., Towart, R., Gregersen, M., Refsum, H., Karlsson, J.O. Br. J. Pharmacol. (1999) [Pubmed]
  25. A double-blind study of iopromide 300 for peripheral arteriography. Results of a multi-institutional comparison of iopromide with iohexol and iopamidol. Druy, E.M., Bettmann, M.A., Jeans, W. Investigative radiology. (1994) [Pubmed]
  26. Vertebral artery injections of methylglucamine diatrizoate 60%, iopromide, and iotrolan in the rabbit. Thomson, K.R., Wells, D.G., O'Brien, K., Tomkins, D.C., Dixon, R.G. Investigative radiology. (1990) [Pubmed]
  27. No difference among modern contrast media's effect on neointimal proliferation and restenosis after coronary stenting in pigs. Clauss, W., Scheller, B., Schmitt, A., Sovak, M., Speck, U. Investigative radiology. (2003) [Pubmed]
  28. Induction of mitotic micronuclei by X-ray contrast media in human peripheral lymphocytes. Parvez, Z., Kormano, M., Satokari, K., Moncada, R., Eklund, R. Mutat. Res. (1987) [Pubmed]
  29. Et-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia. Liss, P., Carlsson, P.O., Nygren, A., Palm, F., Hansell, P. Acta radiologica (Stockholm, Sweden : 1987) (2003) [Pubmed]
  30. Effect of ionic and nonionic contrast media on fibrinolysis in patients undergoing angiocardiography. Huang, C.H., Voon, W.C., Yen, H.W., Sheu, S.H. The Kaohsiung journal of medical sciences. (2001) [Pubmed]
  31. Renal and hepatic tolerance of nonionic and ionic contrast media in intravenous digital subtraction angiography. Langer, M., Junge, W., Keysser, R., Hasford, J., Jänicke, U.A. Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin. Ergänzungsband. (1989) [Pubmed]
  32. The nonionic radiocontrast medium iopromide does not release endothelin-1 or activate cardiac mast cells during coronary angiography. Simon, M.R., Reher, R.L., Long, P.M., Yellayi, K. Int. Arch. Allergy Immunol. (2003) [Pubmed]
  33. Effects of iopromide on vasoactive peptides and allergy-mediated substances in healthy volunteers. Szolar, D.H., Saeed, M., Flueckiger, F., Preidler, K., Stiskal, M.A., Watzinger, N., Sternthal, H., Horina, J. Investigative radiology. (1995) [Pubmed]
  34. Detection of focal liver lesions at biphasic spiral CT: randomized double-blind study of the effect of iodine concentration in contrast materials. Hänninen, E.L., Vogl, T.J., Felfe, R., Pegios, W., Balzer, J., Clauss, W., Felix, R. Radiology. (2000) [Pubmed]
  35. Safety and efficacy of iopromide in cerebral arteriography. Haughton, V.M., Papke, R.A., Hyland, D., Drayer, B.P., Osborn, A.G., Maravilla, K., Hilal, S.K. Investigative radiology. (1994) [Pubmed]
  36. Efficacy and safety of iopromide for excretory urography. Newhouse, J.H., Landman, J., Lang, E., Amis, E.S., Goldman, S., Khazan, R., Leder, R., Hedgcock, M. Investigative radiology. (1994) [Pubmed]
  37. Acute cardiac tolerance of current contrast media and the new taxane protaxel using iopromide as carrier during porcine coronary angiography and stenting. Scheller, B., Speck, U., Schmitt, A., Clauss, W., Sovak, M., Böhm, M., Stoll, H.P. Investigative radiology. (2002) [Pubmed]
WikiGenes - Universities